Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATYR NASDAQ:BLUE NASDAQ:ENGN NASDAQ:VYGR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATYRaTyr Pharma$0.97-0.7%$2.69$0.68▼$7.29$94.62M0.7910.62 million shs2.75 million shsBLUEbluebird bio$4.97$4.78$3.20▼$25.10$48.67M0.27452,966 shsN/AENGNenGene$8.27+5.2%$6.47$2.65▼$9.85$423.10M-0.27374,538 shs104,434 shsVYGRVoyager Therapeutics$4.65+2.2%$4.30$2.64▼$7.44$257.93M0.95820,131 shs421,476 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATYRaTyr Pharma-0.74%-5.33%+1.54%-83.44%-70.56%BLUEbluebird bio0.00%0.00%0.00%0.00%-51.53%ENGNenGene+5.22%-11.55%+18.48%+123.51%-11.46%VYGRVoyager Therapeutics+2.20%-6.06%+9.41%+43.52%-27.68%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATYRaTyr Pharma$0.97-0.7%$2.69$0.68▼$7.29$94.62M0.7910.62 million shs2.75 million shsBLUEbluebird bio$4.97$4.78$3.20▼$25.10$48.67M0.27452,966 shsN/AENGNenGene$8.27+5.2%$6.47$2.65▼$9.85$423.10M-0.27374,538 shs104,434 shsVYGRVoyager Therapeutics$4.65+2.2%$4.30$2.64▼$7.44$257.93M0.95820,131 shs421,476 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATYRaTyr Pharma-0.74%-5.33%+1.54%-83.44%-70.56%BLUEbluebird bio0.00%0.00%0.00%0.00%-51.53%ENGNenGene+5.22%-11.55%+18.48%+123.51%-11.46%VYGRVoyager Therapeutics+2.20%-6.06%+9.41%+43.52%-27.68%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATYRaTyr Pharma 2.00Hold$23.252,307.83% UpsideBLUEbluebird bio 2.17Hold$25.75418.11% UpsideENGNenGene 2.75Moderate Buy$19.50135.79% UpsideVYGRVoyager Therapeutics 2.71Moderate Buy$12.96178.60% UpsideCurrent Analyst Ratings BreakdownLatest BLUE, VYGR, ENGN, and ATYR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/24/2025ATYRaTyr PharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/24/2025VYGRVoyager TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)10/14/2025ENGNenGeneWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025ATYRaTyr PharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025VYGRVoyager TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)9/27/2025ATYRaTyr PharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025ENGNenGeneWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025VYGRVoyager TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)9/15/2025ATYRaTyr PharmaJones TradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold9/15/2025ATYRaTyr PharmaLeerink PartnrsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold9/15/2025ATYRaTyr PharmaWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight(Data available from 10/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATYRaTyr PharmaN/AN/AN/AN/A$0.83 per shareN/ABLUEbluebird bio$103.95M0.47N/AN/A$35.59 per share0.14ENGNenGeneN/AN/AN/AN/A$5.35 per shareN/AVYGRVoyager Therapeutics$80M3.22N/AN/A$5.49 per share0.85Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATYRaTyr Pharma-$64.02M-$0.80N/AN/AN/AN/A-93.69%-68.83%11/6/2025 (Estimated)BLUEbluebird bio-$211.91M-$41.32N/AN/AN/A-565.74%-322.46%-53.17%N/AENGNenGene-$55.14M-$1.90N/AN/AN/AN/A-39.86%-34.15%12/18/2025 (Estimated)VYGRVoyager Therapeutics-$65M-$1.85N/AN/AN/A-253.49%-37.65%-28.89%11/11/2025 (Estimated)Latest BLUE, VYGR, ENGN, and ATYR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025VYGRVoyager Therapeutics-$0.53N/AN/AN/A$7.86 millionN/A11/6/2025Q3 2025ATYRaTyr Pharma-$0.19N/AN/AN/AN/AN/A9/11/2025Q3 2025ENGNenGene-$0.5084-$0.57-$0.0616-$0.57N/AN/A8/7/2025Q2 2025ATYRaTyr Pharma-$0.18-$0.22-$0.04-$0.22N/AN/A8/6/2025Q2 2025VYGRVoyager Therapeutics-$0.48-$0.57-$0.09-$0.57$9.50 million$5.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATYRaTyr PharmaN/AN/AN/AN/AN/ABLUEbluebird bioN/AN/AN/AN/AN/AENGNenGeneN/AN/AN/AN/AN/AVYGRVoyager TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATYRaTyr Pharma0.015.635.63BLUEbluebird bio0.370.510.33ENGNenGene0.0910.3410.34VYGRVoyager TherapeuticsN/A5.435.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATYRaTyr Pharma61.72%BLUEbluebird bio87.43%ENGNenGene64.16%VYGRVoyager Therapeutics48.03%Insider OwnershipCompanyInsider OwnershipATYRaTyr Pharma3.70%BLUEbluebird bio1.40%ENGNenGene10.40%VYGRVoyager Therapeutics6.39%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATYRaTyr Pharma5397.99 million94.36 millionOptionableBLUEbluebird bio5209.79 million9.59 millionOptionableENGNenGene3151.19 million45.87 millionN/AVYGRVoyager Therapeutics10055.47 million51.93 millionOptionableBLUE, VYGR, ENGN, and ATYR HeadlinesRecent News About These CompaniesVoyager Therapeutics (NASDAQ:VYGR) Receives Sell (D) Rating from Weiss RatingsOctober 25 at 7:57 PM | marketbeat.comVoyager Therapeutics, Inc. (NASDAQ:VYGR) Given Average Rating of "Moderate Buy" by AnalystsOctober 13, 2025 | marketbeat.comVoyager Therapeutics (NASDAQ:VYGR) Earns Sell (D) Rating from Weiss RatingsOctober 9, 2025 | marketbeat.comVoyager Therapeutics (VYGR) Soars 11.6%: Is Further Upside Left in the Stock?October 9, 2025 | zacks.comVoyager Therapeutics (NASDAQ:VYGR) CFO Sells $36,643.48 in StockOctober 8, 2025 | insidertrades.comVoyager Therapeutics (NASDAQ:VYGR) CFO Nathan Jorgensen Sells 7,666 SharesOctober 7, 2025 | marketbeat.comStrs Ohio Makes New Investment in Voyager Therapeutics, Inc. $VYGRSeptember 25, 2025 | marketbeat.comVoyager Therapeutics Alzheimer's Portfolio And ALPL NeuroShuttle Underscore Platform Momentum: AnalystSeptember 16, 2025 | uk.finance.yahoo.comVoyager Therapeutics, Inc. (VYGR) Presents At Citi's Biopharma Back To School Conference TranscriptSeptember 2, 2025 | seekingalpha.comVoyager to Present at Upcoming Investor ConferencesAugust 26, 2025 | globenewswire.comVoyager Therapeutics Extends Cash Runway to 2028August 13, 2025 | msn.comTruist Financial Keeps Their Buy Rating on Voyager Therapeutics (VYGR)August 11, 2025 | theglobeandmail.comVoyager Therapeutics (VYGR) Receives a Buy from OppenheimerAugust 11, 2025 | theglobeandmail.comVoyager Therapeutics (VYGR) Receives a Buy from Canaccord GenuityAugust 9, 2025 | theglobeandmail.comVoyager Therapeutics (VYGR) Reports Q2 Loss, Lags Revenue EstimatesAugust 6, 2025 | zacks.comVoyager Reports Second Quarter 2025 Financial and Operating ResultsAugust 6, 2025 | globenewswire.comVoyager 1 and 2: From Earth to Interstellar Space: The Final Frontier AwaitsJuly 21, 2025 | msn.comRead the NASA ‘Voyager Declaration’ Letter of DissentJuly 21, 2025 | nytimes.comMascarene Partners Acquires Voyager TruckingJuly 18, 2025 | finance.yahoo.comMascarene buys US waste services company Voyager TruckingJuly 18, 2025 | realassets.ipe.comRVoyager Therapeutics adds new gene therapy to Alzheimer’s programJuly 18, 2025 | bioworld.comBNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025October’s Top 5 Stocks Poised for Big BreakoutsBy Thomas Hughes | October 1, 2025Datavault AI: The New AI Contender Backed by Big FundingBy Jeffrey Neal Johnson | October 1, 2025Costco Investors Will Get a “Special” Treat for ChristmasBy Thomas Hughes | September 29, 2025Time to Take Notice: PEGA’s GenAI Blueprint Delivers Huge Q3 BeatBy Leo Miller | October 25, 2025BLUE, VYGR, ENGN, and ATYR Company DescriptionsaTyr Pharma NASDAQ:ATYR$0.97 -0.01 (-0.74%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$0.96 0.00 (-0.17%) As of 10/24/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.bluebird bio NASDAQ:BLUEbluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.enGene NASDAQ:ENGN$8.27 +0.41 (+5.22%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$8.41 +0.14 (+1.68%) As of 10/24/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.Voyager Therapeutics NASDAQ:VYGR$4.65 +0.10 (+2.20%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$4.69 +0.04 (+0.86%) As of 10/24/2025 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 10/20 - 10/24 Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tractor Supply Stock Looks Like a Buy-and-Hold Winner Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
